Lexaria Net Income From Continuing Ops from 2010 to 2026
| LEXX Stock | USD 0.69 0.04 5.48% |
Net Loss | First Reported 2019-11-30 | Previous Quarter -2.7 M | Current Value -1.6 M | Quarterly Volatility 888.7 K |
Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 190.8 K, Interest Expense of 107 K or Total Revenue of 426.9 K, as well as many indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0 or PTB Ratio of 57.61. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
Lexaria | Net Income From Continuing Ops | Build AI portfolio with Lexaria Stock |
The evolution of Net Income From Continuing Ops for Lexaria Bioscience Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Lexaria Bioscience compares to historical norms and industry peers.
Latest Lexaria Bioscience's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Lexaria Bioscience Corp over the last few years. It is Lexaria Bioscience's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexaria Bioscience's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Lexaria Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (5,014,321) | |
| Coefficient Of Variation | (68.26) | |
| Mean Deviation | 2,850,562 | |
| Median | (4,158,413) | |
| Standard Deviation | 3,422,928 | |
| Sample Variance | 11.7T | |
| Range | 10M | |
| R-Value | (0.88) | |
| Mean Square Error | 2.7T | |
| R-Squared | 0.78 | |
| Slope | (598,778) | |
| Total Sum of Squares | 187.5T |
Lexaria Net Income From Continuing Ops History
About Lexaria Bioscience Financial Statements
Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -10.7 M | -10.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.